ClinicalTrials.gg
CompletedNCT01342484Updated Sep 15, 2016Results posted

Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes

A Phase 2 interventional study of placebo and BI1356 low dose in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 25 sites in 9 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2016-09-15.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 67 studies testing linagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Linagliptin · Diabetes Mellitus, Type 2.

Enrollment
53rd of 67
40 · median 175
Started
2011
with 1 other
Phase 2
4 of 67
none open now
Registered
25th of 67
by date
Lead sponsor
36 of 67
Boehringer Ingelheim

Among the 67 studies testing linagliptin in Diabetes Mellitus, Type 2, this one is the 53rd largest by enrollment, is one of 2 that started in 2011, is one of 4 in phase 2, and was the 25th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 67 studies testing linagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About linagliptin

Linagliptin: first FDA approval 2011 (TRADJENTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing linagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The main objective of this study is to identify the dose of linagliptin in paediatric patients.

Other efficacy objectives include the comparison of the lowering effect of linagliptin low dose, high dose and placebo on the fasting plasma glucose (FPG) observed after 12 wk of treatment.

Furthermore, the study will investigate the pharmacokinetics (PK), the pharmacodynamics (PD) and the PK/PD relationship of linagliptin in the paediatric population.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Paediatric patients (children and adolescents), aged 10 to 17 years with documented diagnosis of type 2 diabetes mellitus
  2. Insufficient glycaemic control (i.e. an > 6.5% and \<= 10.5%) despite treatment with diet and exercise and/or metformin (>= 1000 mg per day (or the maximum tolerated dose) at a stable dose or dosing frequency for 8 weeks prior to randomisation) and/or concomitant stable basal insulin (total daily dose must be \<= 0.5U/kg with less than 10% of weekly dose change for 12 weeks prior to randomisation)
  3. Negative for islet cell antigen (ICA) auto-antibodies and glutamic acid decarboxylase (GAD) auto-antibodies
  4. C-peptide levels (serum) >= 1.5 ng/ml (at 90 min following a Boost challenge)

Exclusion criteria

Exclusion criteria:

  1. History of acute metabolic decompensation, such as diabetic ketoacidosis, within 3 months
  2. Current short-acting insulin or having received short-acting insulin for more than 3 days within 1 month prior to randomisation
  3. Treatment with weight reduction medications (including anti-obesity treatments)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
40 participants (actual)

Study arms

  • Experimental
    linagliptin low dose

    linagliptin low dose for children once daily

    Drug: BI1356 low dose

  • Experimental
    linagliptin high dose

    linagliptin high dose for children once daily

    Drug: BI1356 high dose

  • Placebo comparator
    placebo

    matching placebo for each linagliptin dose once daily

    Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%) After 12 Weeks of Treatment

    Change from baseline in Glycosylated haemoglobin (HbA1c) \[%\] after 12 weeks of treatment with double-blind trial medication. Baseline was defined as the last observation before the first intake of any double-blind randomised trial medication. The number of participants analysed displays the number of participants with available data at the timepoint of interest.

    Time frame: Baseline and 12 weeks

Secondary outcomes

  1. Dipeptidyl-peptidase-4 (DPP-4) Inhibition (%) at Trough at Steady State

    DPP-4 inhibition (%) at trough at steady state is the relative change between the measurement of DPP-4 activity taken 0.5 hours before dosing at baseline and the first available on-treatment measurement of DPP-4 activity taken 0.5 hour before dosing at week 4, 8 or 12: DPP-4 inhibition (%) = 100 - (DPP-4 activity at week X / DPP-4 activity at baseline) x 100.

    Time frame: Baseline and 4 weeks or 8 weeks or 12 weeks

  2. Change From Baseline in Fasting Plasma Glucose (FPG) After 12 Weeks of Treatment

    Change from baseline in FPG (mmol/L) after 12 weeks of treatment with double-blind trial medication. The number of participants analysed displays the number of participants with available data at the timepoint of interest.

    Time frame: Baseline and 12 weeks

07

Results

Posted Sep 15, 2016

Participant flow

Randomised, double-blind, placebo-controlled parallel group dose-finding study of linagliptin over 12 weeks in children and adolescents, from 10 to 17 years of age, with type 2 diabetes mellitus. Due to serious Good clinical practice (GCP) breach, 1 patient excluded from all analyses. So protocol section has 40 subjects and participant flow has 39

Participant flow — Overall Study
MilestonePlaceboLinagliptin 1 mgLinagliptin 5 mg
Started151014
Completed131013
Not completed201
Withdrew: Other reasons100
Withdrew: Protocol violation001
Withdrew: Withdrawal by subject100

Outcome measures

PrimaryChange From Baseline in Glycosylated Haemoglobin (HbA1c) (%) After 12 Weeks of Treatment

Change from baseline in Glycosylated haemoglobin (HbA1c) \[%\] after 12 weeks of treatment with double-blind trial medication. Baseline was defined as the last observation before the first intake of any double-blind randomised trial medication. The number of participants analysed displays the number of participants with available data at the timepoint of interest.

Time frame:
Baseline and 12 weeks
Reported as:
Least squares mean · Percentage of HbA1c
Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%) After 12 Weeks of Treatment
Percentage of HbA1cPlaceboLinagliptin 1 mgLinagliptin 5 mg
Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%) After 12 Weeks of Treatment0.45 ± 0.31-0.03 ± 0.38-0.19 ± 0.30
Statistical analysis
  • Placebo vs Linagliptin 1 mg · Mixed Models Analysis · p = 0.3295 · Mean difference (net): -0.48 · 95% CI -1.47 to 0.51Mean Difference (Net Values) is actually the adjusted mean difference calculated as Linagliptin 1 mg minus Placebo.
  • Placebo vs Linagliptin 5 mg · Mixed Models Analysis · p = 0.1447 · Mean difference (net): -0.63 · 95% CI -1.50 to 0.23Mean Difference (Net Values) is actually the adjusted mean difference calculated as Linagliptin 5 mg minus Placebo.
SecondaryDipeptidyl-peptidase-4 (DPP-4) Inhibition (%) at Trough at Steady State

DPP-4 inhibition (%) at trough at steady state is the relative change between the measurement of DPP-4 activity taken 0.5 hours before dosing at baseline and the first available on-treatment measurement of DPP-4 activity taken 0.5 hour before dosing at week 4, 8 or 12: DPP-4 inhibition (%) = 100 - (DPP-4 activity at week X / DPP-4 activity at baseline) x 100.

Time frame:
Baseline and 4 weeks or 8 weeks or 12 weeks
Reported as:
Median · Percentage of DPP-4 inhibition
Dipeptidyl-peptidase-4 (DPP-4) Inhibition (%) at Trough at Steady State
Percentage of DPP-4 inhibitionPlaceboLinagliptin 1 mgLinagliptin 5 mg
Dipeptidyl-peptidase-4 (DPP-4) Inhibition (%) at Trough at Steady State—38.4 (26.9 to 48.8)78.9 (67.7 to 84.0)
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) After 12 Weeks of Treatment

Change from baseline in FPG (mmol/L) after 12 weeks of treatment with double-blind trial medication. The number of participants analysed displays the number of participants with available data at the timepoint of interest.

Time frame:
Baseline and 12 weeks
Reported as:
Least squares mean · mmol/L
Change From Baseline in Fasting Plasma Glucose (FPG) After 12 Weeks of Treatment
mmol/LPlaceboLinagliptin 1 mgLinagliptin 5 mg
Change From Baseline in Fasting Plasma Glucose (FPG) After 12 Weeks of Treatment1.70 ± 0.851.39 ± 1.07-0.19 ± 0.83
Statistical analysis
  • Placebo vs Linagliptin 1 mg · Mixed Models Analysis · p = 0.8216 · Mean difference (net): -0.31 · 95% CI -3.08 to 2.46Mean Difference (Net Values) is actually the adjusted mean difference calculated as Linagliptin 1 mg minus Placebo.
  • Placebo vs Linagliptin 5 mg · Mixed Models Analysis · p = 0.1189 · Mean difference (net): -1.90 · 95% CI -4.31 to 0.52Mean Difference (Net Values) is actually the adjusted mean difference calculated as Linagliptin 5 mg minus Placebo.

Adverse events

Collected over From the first intake of study drug until 7 days after the last drug administration, up to 13 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/15 (6.7%)7/15 (46.7%)
Linagliptin 1 mg—0/10 (0%)8/10 (80%)
Linagliptin 5 mg—0/14 (0%)6/14 (42.9%)
Most frequent serious events
Most frequent serious events
EventPlaceboLinagliptin 1 mgLinagliptin 5 mg
HyperglycaemiaMetabolism and nutrition disorders1/150/100/14
Most frequent other events
Showing 10 of 24
Most frequent other events
EventPlaceboLinagliptin 1 mgLinagliptin 5 mg
NasopharyngitisInfections and infestations1/153/100/14
HeadacheNervous system disorders1/150/104/14
HyperglycaemiaMetabolism and nutrition disorders0/152/100/14
Eye haemorrhageEye disorders0/151/100/14
DiarrhoeaGastrointestinal disorders0/151/100/14
Conjunctivitis bacterialInfections and infestations0/151/100/14
Blood creatinine increasedInvestigations0/151/100/14
DizzinessNervous system disorders0/151/100/14
ParaesthesiaNervous system disorders0/151/101/14
MenorrhagiaReproductive system and breast disorders0/151/100/14

Baseline characteristics

Treated set (TS) including all patients who were treated with at least one dose of study drug.

Age, Continuous
Age, Continuous(Years)PlaceboLinagliptin 1 mgLinagliptin 5 mgTotal
Mean13.7 ± 2.014.0 ± 1.814.3 ± 2.114.0 ± 1.9
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLinagliptin 1 mgLinagliptin 5 mgTotal
Female84921
Male76518
08

Study locations

25 sites
  • 1218.56.01006 Boehringer Ingelheim Investigational Site
    San Antonio, Texas, United States
  • 1218.56.01004 Boehringer Ingelheim Investigational Site
    Norfolk, Virginia, United States
  • 1218.56.11001 Boehringer Ingelheim Investigational Site
    Montreal, Quebec, Canada
  • 1218.56.33003 Boehringer Ingelheim Investigational Site
    Fort de France cedex, France
  • 1218.56.33006 Boehringer Ingelheim Investigational Site
    Rouen, France
  • 1218.56.50202 Boehringer Ingelheim Investigational Site
    Guatemala, Guatemala
  • 1218.56.50203 Boehringer Ingelheim Investigational Site
    Guatemala, Guatemala
  • 1218.56.39005 Boehringer Ingelheim Investigational Site
    Firenze, Italy
  • 1218.56.82005 Boehringer Ingelheim Investigational Site
    Busan, Korea, Republic of
  • 1218.56.82001 Boehringer Ingelheim Investigational Site
    Seoul, Korea, Republic of
  • 1218.56.82002 Boehringer Ingelheim Investigational Site
    Seoul, Korea, Republic of
  • 1218.56.82003 Boehringer Ingelheim Investigational Site
    Suwon, Korea, Republic of
  • 1218.56.52008 Boehringer Ingelheim Investigational Site
    Chihuahua, Mexico
  • 1218.56.52002 Boehringer Ingelheim Investigational Site
    Guadalajara, Mexico
  • 1218.56.52001 Boehringer Ingelheim Investigational Site
    León, Mexico
  • 1218.56.52003 Boehringer Ingelheim Investigational Site
    Monterrey, Mexico
  • 1218.56.52004 Boehringer Ingelheim Investigational Site
    Oaxaca, Mexico
  • 1218.56.48002 Boehringer Ingelheim Investigational Site
    Gdansk, Poland
  • 1218.56.48001 Boehringer Ingelheim Investigational Site
    Gliwice, Poland
  • 1218.56.48004 Boehringer Ingelheim Investigational Site
    Warszawa, Poland
  • 1218.56.48003 Boehringer Ingelheim Investigational Site
    Wroclaw, Poland
  • 1218.56.70001 Boehringer Ingelheim Investigational Site
    Moscow, Russian Federation
  • 1218.56.70003 Boehringer Ingelheim Investigational Site
    Saratov, Russian Federation
  • 1218.56.70004 Boehringer Ingelheim Investigational Site
    Ufa, Russian Federation
  • 1218.56.70006 Boehringer Ingelheim Investigational Site
    Yekaterinburg, Russian Federation
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2011, a primary completion of Feb 2016 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2016, 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2011
First posted
Apr 27, 2011
Start
Apr 2011
Primary completionActual
Feb 2016
CompletionActual
Feb 2016
Results first posted
Sep 15, 2016
Last update
Sep 15, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01342484
Responsible party
Sponsor
First posted
Apr 27, 2011
Start date
Apr 2011
Primary completion
Feb 2016
Completion
Feb 2016
Results posted
Sep 15, 2016
Last update
Sep 15, 2016

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linagliptin

Start the discussion